Novartis to bolster its oncology portfolio with acquisition of MorphoSys
Novartis to bolster its oncology portfolio with acquisition of MorphoSys
114
views
Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).
Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).

Comments

https://stocktradingwebsites.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!